LAFAYETTE, La. - The Louisiana federal judge overseeing the Actos multidistrict litigation on Dec. 19 said that a plaintiff in the first bellwether trial can present expert testimony that use of the type 2 diabetes drug can cause bladder cancer within one year of use (In Re: Actos $(Pioglitazone$) Products Liability Litigation, MDL Docket No. 2299, No. 6:11-md-2299, Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al., No. 12-64, W.D. La., Lafayette Div.).